0001703057-23-000032.txt : 20230926
0001703057-23-000032.hdr.sgml : 20230926
20230926122607
ACCESSION NUMBER: 0001703057-23-000032
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230922
FILED AS OF DATE: 20230926
DATE AS OF CHANGE: 20230926
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hayden Michael R
CENTRAL INDEX KEY: 0001352908
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39781
FILM NUMBER: 231279130
MAIL ADDRESS:
STREET 1: C/O ASPREVA PHARMACEUTICALS CORPORATION
STREET 2: 1203-4464 MARKHAM STREET
CITY: VICTORIA
STATE: A1
ZIP: V8Z 7X8
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AbCellera Biologics Inc.
CENTRAL INDEX KEY: 0001703057
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A1
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2215 YUKON STREET
CITY: VANCOUVER
STATE: A1
ZIP: V5Y 0A1
BUSINESS PHONE: (604) 559-9005
MAIL ADDRESS:
STREET 1: 2215 YUKON STREET
CITY: VANCOUVER
STATE: A1
ZIP: V5Y 0A1
4
1
wk-form4_1695745559.xml
FORM 4
X0508
4
2023-09-22
0
0001703057
AbCellera Biologics Inc.
ABCL
0001352908
Hayden Michael R
C/O ABCELLERA BIOLOGICS INC
2215 YUKON STREET
VANCOUVER
A1
BRITISH COLUMBIA, CANADA
1
0
0
0
0
Common Shares
2023-09-22
5
P
0
E
20000
4.91
A
1323397
I
See footnote
Common Shares
118245
I
By spouse
The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $4.89 to $4.93. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.
These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein.
Tryn Stimart, attorney-in-fact
2023-09-26